Union of India v. Pfizer Limited
In short. The case revolves around the interpretation of Section 26A of the Drugs and Cosmetics Act, 1940, specifically whether prior consultation with the Drugs Technical Advisory Board (DTAB) is a mandatory condition for the Central Government to exercise its powers under this section. The Delhi High Court ruled that such consultation is indeed mandatory, diverging from previous judgments by the Karnataka and Madras High Courts which held otherwise. The Supreme Court upheld the Delhi High Court's interpretation, emphasizing the importance of DTAB's role in ensuring the safety and efficacy of Fixed Dose Combinations (FDCs) in the Indian market.
Facts
The case originated from concerns regarding the proliferation of FDCs in India, many of which had not been tested for safety or efficacy. The Parliamentary Standing Committee on Health and Family Welfare highlighted these issues in its 59th Report in May 2012, noting that numerous FDCs were being licensed without proper clearance from the Central Drugs Standard Control Organization (CDSCO). Following this report, the Ministry of Health issued directives to prevent the licensing of FDCs that were classified as "new drugs" without CDSCO approval. The Delhi High Court's judgment on December 1, 2016, addressed the legal interpretation of Section 26A in light of these developments.
Arguments
Petitioner Arguments
The petitioners, Union of India and others, argued that the consultation with DTAB was not a mandatory prerequisite for exercising powers under Section 26A. They contended that the interpretation of the law should allow for flexibility in urgent situations where public health is at risk due to unregulated FDCs. The court, however, found that the statutory language and the legislative intent clearly indicated that prior consultation was necessary to ensure that decisions made by the Central Government were informed by expert advice.
Respondent Arguments
The respondents, Pfizer Limited and others, supported the Delhi High Court's ruling, asserting that the mandatory consultation with DTAB is essential for maintaining the integrity of drug regulation in India. They argued that bypassing this requirement could lead to unsafe drugs entering the market, thereby endangering public health. The court agreed with this perspective, reinforcing the importance of expert oversight in drug approvals.
Precedents considered
The judgment referenced previous rulings from the Karnataka and Madras High Courts, which had interpreted Section 26A differently. However, the Supreme Court chose to uphold the Delhi High Court's interpretation, emphasizing the need for a consistent approach to drug regulation that prioritizes public safety.
Legal principles
The court considered the legal principle that statutory provisions must be interpreted in a manner that aligns with their purpose and the broader legislative framework. The necessity of consulting DTAB was viewed as a safeguard against the potential risks posed by untested FDCs, reflecting a commitment to public health and safety.
Decision and reasoning
Rationale
The court's reasoning centered on the interpretation of statutory language and the legislative intent behind Section 26A. It highlighted the importance of expert consultation in regulatory decisions, particularly in the context of public health. The court criticized the previous interpretations that allowed for flexibility without consultation, arguing that such an approach could undermine the regulatory framework designed to protect consumers.
Outcome
The Supreme Court upheld the Delhi High Court's decision, affirming that prior consultation with DTAB is mandatory before the Central Government can exercise its powers under Section 26A of the Drugs Act. The court did not provide specific instructions for the appeal process, as the focus was on the interpretation of the law rather than procedural matters.
Conclusion
This judgment reinforces the necessity of expert consultation in drug regulation, highlighting the court's commitment to public health and safety. It sets a significant precedent for future cases involving the approval of pharmaceuticals, ensuring that regulatory decisions are informed by scientific and technical expertise.
Read the full judgment on the Supreme Court website (PDF)
Find the judgments that followed or distinguished it, with the paragraph relied on in each. Two answers free on WhatsApp, no signup.